Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$18.73
+3.0%
$20.73
$7.41
$24.17
$1.43B0.851.35 million shs1.04 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$16.23
+5.3%
$16.82
$4.29
$21.88
$1.02B2.11.43 million shs646,310 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.89
+0.5%
$2.24
$1.86
$4.73
$21.79M1.0321,344 shs20,700 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$8.18
+2.9%
$7.32
$3.05
$9.96
$249.08M1.4562,645 shs154,375 shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+3.76%-4.31%-15.00%+35.54%+65.36%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-1.28%-9.03%+6.42%+28.31%+121.73%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00%-4.62%-18.78%-19.48%-50.27%
XBiotech Inc. stock logo
XBIT
XBiotech
-1.12%-15.52%+6.00%+74.73%+129.77%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3.2119 of 5 stars
3.41.00.04.71.90.80.0
MacroGenics, Inc. stock logo
MGNX
MacroGenics
3.2855 of 5 stars
2.41.00.04.41.83.30.6
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.88
Moderate Buy$28.2850.98% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.88
Moderate Buy$17.004.74% Upside
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.00
HoldN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A

Current Analyst Ratings

Latest ZIOP, KURA, MGNX, XBIT, and TXMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
4/9/2024
MacroGenics, Inc. stock logo
MGNX
MacroGenics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/4/2024
MacroGenics, Inc. stock logo
MGNX
MacroGenics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform
3/6/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
3/4/2024
MacroGenics, Inc. stock logo
MGNX
MacroGenics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $24.00
2/29/2024
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$12.00 ➝ $23.00
2/28/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
2/28/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$37.00
2/14/2024
MacroGenics, Inc. stock logo
MGNX
MacroGenics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$12.00 ➝ $14.00
1/31/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$22.00 ➝ $32.00
1/24/2024
MacroGenics, Inc. stock logo
MGNX
MacroGenics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/A$5.35 per shareN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$58.75M17.28N/AN/A$2.46 per share6.60
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.30M16.76N/AN/A$2.77 per share0.68
XBiotech Inc. stock logo
XBIT
XBiotech
$4.01M62.11N/AN/A$7.19 per share1.14
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$152.63M-$2.08N/AN/AN/AN/A-36.30%-33.12%5/8/2024 (Estimated)
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$9.06M-$0.16N/AN/AN/A-15.42%-88.49%-43.12%5/14/2024 (Estimated)
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/AN/A-25.54%-14.87%5/20/2024 (Estimated)
XBiotech Inc. stock logo
XBIT
XBiotech
-$24.56M-$0.82N/AN/AN/A-10.82%-10.52%5/8/2024 (Estimated)
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest ZIOP, KURA, MGNX, XBIT, and TXMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/15/2024Q4 2023
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.16-$0.16-$0.16N/AN/A
3/7/2024Q4 2023
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.26-$0.75-$0.49-$0.75$25.70 million$10.72 million    
2/27/2024Q4 2023
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.56-$0.55+$0.01-$0.55N/AN/A    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
12.26
12.26
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
4.48
4.46
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
1.72
1.72
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
33.07
33.07
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%

Insider Ownership

CompanyInsider Ownership
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
5.50%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
11.30%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.20%
XBiotech Inc. stock logo
XBIT
XBiotech
28.40%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
5.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
14276.18 million71.99 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
33962.56 million55.49 millionOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
111.53 million11.39 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
8230.45 million21.80 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

ZIOP, KURA, MGNX, XBIT, and TXMD Headlines

SourceHeadline
Childhood CancersChildhood Cancers
curetoday.com - February 17 at 5:57 PM
Alx Oncology Holdings (ALXO)Alx Oncology Holdings (ALXO)
investing.com - February 10 at 8:15 PM
Pediatric Hematology-Oncology FellowshipPediatric Hematology-Oncology Fellowship
bcm.edu - February 5 at 8:39 AM
Alaunos Therapeutics: Other Events, Financial Statements And ExhibitsAlaunos Therapeutics: Other Events, Financial Statements And Exhibits
cbonds.com - January 31 at 9:44 AM
CG Oncology IncCG Oncology Inc
reuters.com - January 31 at 4:43 AM
Oncology Nurses Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients
medscape.com - December 21 at 3:43 PM
Immuno-OncologyImmuno-Oncology
ajmc.com - December 19 at 3:21 PM
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
markets.businessinsider.com - December 18 at 8:18 AM
Exploring Patient-Centered Handoffs in Surgical OncologyExploring Patient-Centered Handoffs in Surgical Oncology
medscape.com - December 10 at 7:36 PM
Association of Community Cancer CentersAssociation of Community Cancer Centers
ajmc.com - October 14 at 2:50 PM
Oncology News and ResearchOncology News and Research
news-medical.net - September 19 at 5:53 PM
WBSPH 2024 - OncologyWBSPH 2024 - Oncology
newsweek.com - September 15 at 8:49 PM
Kris on OncologyKris on Oncology
medscape.com - September 6 at 11:16 PM
Gauging Ziopharms Chances for Positive Sarcoma Drug Trial ResultsGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
thestreet.com - August 29 at 6:23 AM
Oncology Cases & QuizzesOncology Cases & Quizzes
medscape.com - August 14 at 6:15 PM
Ziopharm’s palifosfamide fails in first-line STS…Ziopharm’s palifosfamide fails in first-line STS…
investing.com - June 21 at 12:05 AM
Weber on OncologyWeber on Oncology
medscape.com - June 19 at 2:11 PM
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in MelanomaA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
ascopubs.org - June 17 at 8:43 AM
ALX Oncology Holdings Inc Ordinary SharesALX Oncology Holdings Inc Ordinary Shares
morningstar.com - June 15 at 6:54 PM
Division of Pediatric Hematology and OncologyDivision of Pediatric Hematology and Oncology
slu.edu - June 13 at 3:50 PM
Division of Hematology and Medical OncologyDivision of Hematology and Medical Oncology
slu.edu - June 13 at 3:50 PM
Intratumoral Cancer Therapies Global Market Report 2023Intratumoral Cancer Therapies Global Market Report 2023
finance.yahoo.com - June 9 at 1:32 PM
Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co
marketwatch.com - May 11 at 9:52 PM
VC Identifies 3 Startups That Will Shake Up the Future of Cancer CareVC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
medcitynews.com - May 10 at 1:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Kura Oncology logo

Kura Oncology

NASDAQ:KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
MacroGenics logo

MacroGenics

NASDAQ:MGNX
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
TherapeuticsMD logo

TherapeuticsMD

NASDAQ:TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
XBiotech logo

XBiotech

NASDAQ:XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
ZIOPHARM Oncology logo

ZIOPHARM Oncology

NASDAQ:ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.